Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Quantum Pharmics jumped into the benzodiazepine market with the approval of its lorazepam ANDA by FDA on Aug. 9. The agency approved three dosage forms of the anti-anxiety agent, 0.5 mg, 1 mg, and 2 mg tabs. The generic version of Wyeth's Ativan is the second post-1962 ANDA approval in two weeks for the Amityville, NY-based Quantum Pharmics. On July 29, the company received approval to market the gastric motility agent metoclopramide (10 mg tabs), the generic to Robins Reglan. HHS highlighted the lorazepam approval in a press release Aug. 13, noting that the drug is the sixth post-1962 generic approved since enactment of the ANDA/patent restoration law in November 1984. The other post-1962 drugs that have cleared the agency are dysopyramide, propoxyphene napsylate with acetaminophen, metoclopramide, propranolol HCI and ibuprofen. In all, 12 separate ANDA's for the post 1962 products have been approved. The HHS release said Ativan "ranks 22 in the top 100 selling drugs in the U.S. with 1984 sales of about" $150 mil. Pharmaceutical Data Services projected 1984 Ativan sales in the U.S. at $102 mil. at pharmacy cost. With the lorezapam approval, American Home Products' top two Rx products have become multisource drugs within a two week period. On July 30, Lederle and Chelsea received ANDA approval for generic propranolol, which Lederle said it would sell for 30-35% less than American Home's brand name product, Inderal. In addition, Martec received an ANDA for propranolol on Aug. 6. Zenith is now marketing the Martec product.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts